← Human Trials & Peer-Reviewed Studies
Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study
Plain-language guide to PMID 31704740 (2020): randomized controlled trial study of Vitamin D, K2, Magnesium and Zinc in 132 patients.
Key Facts
- PMID
- 31704740
- Journal
- Journal of the American Society of Nephrology : JASN
- Year
- 2020
- Study type
- Randomized Controlled Trial
- Authors
- De Vriese AS et al. (10 authors)
- DOI
- 10.1681/ASN.2019060579
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.
Systemic dp-ucMGP levels were quantified to assess vascular vitamin K status.
Cardiac and thoracic aorta calcium scores and pulse wave velocity were measured to evaluate VC progression.
Why It Was Studied
Functional vitamin K deficiency may further contribute to their susceptibility for VC.
The researchers investigated the effect of vitamin K status on VC progression in 132 patients on hemodialysis with atrial fibrillation treated with VKAs or qualifying for anticoagulation.
Who Took Part
The study group was 132 patients.
PubMed indexes the participants as older adults and people over 80, both men and women.
How the Study Was Run
The design is described as randomized.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The timeline in the abstract includes 18 months.
What Was Measured
Topics PubMed links to this paper include Antifibrinolytic Agents, Atrial Fibrillation, Factor Xa Inhibitors, Fibrinolytic Agents, Renal Dialysis, Rivaroxaban and Stroke.
The authors tagged it with the keywords direct oral anticoagulant, hemodialysis, oral anticoagulation, vascular calcification, vitamin K and vitamin K antagonist.
What This Means in Plain Language
The paper is a randomized study of Vitamin D, K2, Magnesium and Zinc in 132 patients over 18 months.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2020 (Journal of the American Society of Nephrology : JASN), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.